Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
32/1 reverse split.... check NTRPD
Page 4, under stockholder deficit. 960mil+ 480mil:
Stockholders' Deficit
Preferred stock, $0.001 par value; 20,000,000 shares authorized;
Preferred stock, Series 'A' 22,034 shares issued and outstanding
22 22
Preferred stock, Series 'C' 1,587,145 and 87,145 shares issued and outstanding
1,587 87
Common stock, $0.001 par value, voting, 960,000,000 and 480,000,000 shares authorized, 472,951,421 and 54,691,581 issued and outstanding
472,760 54,500
Additional paid-in capital
26,269,307 23,012,265
Accumulated deficit
(32,039,372 ) (28,013,077 )
Reciprocal shareholdings
(1,550,001 ) (1,550,001 )
Total stockholders’ deficit
(6,845,697 ) (6,496,204 )
Total liabilities and stockholders' deficit
$ 1,009,566 $ 1,000,389
The accompanying notes are an integral part of these consolidated financial statements
Disregard, it changed back lol
Ask is at .0002x 1mil.... hmmmm
I just read them, one is about changing their accountant and the other is about a chump change loan.... if you have shares at .005 and under your golden, this may run to .015-.03 but after that take your $$$$ and find the next 3x bagger
Hey I'm not against tossing a few bucks in for a lotto ticket but some statements are CRAZY, the last press release was over a year ago, this might run to .015-.03..... but without real news from the company itself it won't last
Fair enough, but if they're signing multi million dollar contracts , why are they borrowing $400k? Why the skull and crossbones?
I'm not saying you can't make money here, there enough positive stuff going on but claiming GOOGLE AND APPLE? that screams "scam".... stick with the truth.... google can buy the company for what it spends on its holiday party. They just borrowed $400,000 on a loan a month ago.... that doesn't sound like a company GOOGLE AND APPLE will "invest" in
Come on, Google and Apple? This company has a $6 mil market cap and has the red skull and bones, not longer reporting to OTC, trading at .008..... I see the value of a run here but google and apple? What are they investing $500?? A lot of things can give this company value, when statements like that are made it scares people away....
We don't know whether or not elite can accomplish that Tmax delay because they hadn't done a fed Tmax study at the time of submission.... I was just curious to know what the Tmax was. It can be assumed, which is strictly my speculation, that the fed Tmax delay test is what elite and the FDA agreed to, being that it is the current protocol for drugs of this kind.
Here is the info regarding the CRL from the conference call:
"They FDA is studying our proposal, and they will give us feedback soon. They have given us a date to meet us in the third week of December. We believe that our proposal will address the FDA Tmax concern, and if they agree with our proposal and we will know that next month, Elite will complete additional work and a fed BE study and target resubmission in 2017. We will know more after we meet with the FDA."
Recently, on 12/22/16, the company updated shareholders that the FDA and Elite have come to an agreement regarding a path forward for approval and will update at end of this month, which can be a HUGE catalyst considering it will be the first drug of its kind...tie that in with all the political and media coverage about opioid abuse and I think we might have a winner
This is taken from ELITES board posted by another member but he is simply quoting the CEO
Quote:
Elites ARTechnology is solid. FDA could not find any issues with it.
Extended Release opiods will be a breeze due to no outrageous Tmax requirements with ER opiods.
Quote:
Third, SequestOx. Adjacently the requirements are underway. On July 18, I updated you on the FDAs response, that was only 3 weeks ago. In the past three weeks we ran a multitude of invitro experimentation that stimulated different oily, fatty, acidic, stomach and intestines. We have 3 proposals for the FDA to evaluate that would reduce or eliminate the Tmax delay. We can demonstrate this, WE ARE B.E." !!!!
The CRL was regarding TMax and food effect, the drug itself is bioequivelant...the FDA needs food effect data, they didn't have a problem with Sequestox abuse deterrent technology.... according to the CEO they can provide it, I will post the info momentarily
Looks like it simmered down a bit
$heff.... what's your take on elite pharmaceuticals sequestox ? They had a meeting with FDA regarding the only potential abuse deterrent immediate release opioid on 12/22... with an update that there is a very potential approval on the horizon, currently trading at .165 , but ran to .97 upon first submission...
If you read further down it states
"Similar effects of food are expected with the 15 mg and 30 mg tablets."
And that was good enough to get FDA approval
WRONG!!
Actually here is their stance, they CAN RECOMMEND the product be sprinkled....
"VI. OTHER CONSIDERATIONS A. Sprinkles
In NDAs, the labeling of certain drug products (e.g., controlled-release capsules containing beads) can recommend that the product be sprinkled on soft foods, such as applesauce, and swallowed without chewing. For the labeling to indicate that the drug product can be sprinkled on soft foods, additional in vivo relative BA studies should be performed by sprinkling the product on the soft foods to be listed in the labeling (test treatment) and comparing it to the product administered in the intact form (reference treatment), then administering both on an empty stomach.
In ANDAs, BE of the test to the RLD is demonstrated in a single dose crossover study. Both treatments should be sprinkled on one of the soft foods mentioned in the labeling, usually applesauce. The BE data should be analyzed using average BE and the 90 percent CI criteria should be used to declare BE. If there are questions about other foods, the design, or the analysis of such BE studies, the sponsors and/or applicants should contact the Office of Generic Drugs.
Does anyone know what our current TMax delay time is with sequestox? I know the currently approved roxicodone one is as follows
"Food Effect: A single-dose food effect study was conducted in normal volunteers using the 5 mg/5 mL solution. The concurrent intake of a high fat meal was shown to enhance the extent (27% increase in AUC), but not the rate of oxycodone absorption from the oral solution (see Table 1). In addition, food caused a delay in Tmax (1.25 to 2.54 hour). Similar effects of food are expected with the 15 mg and 30 mg tablets."
So if Elite can come within comparable measures to 1.25-2.5 hours then we should be good.
Probably good top line results coming soon...
Well we'll see when the ask goes up, only 10.5 million left, hopefully no more .0001s behind those.
Absolutely.
Mentioned on financial buzz this morning..... starting to get more attention...
http://www.prnewswire.com/news-releases/trending-small-cap-companies-with-news-610252565.html
Politics, you think the political atmosphere won't sway insurance companies to cover abuse deterrent narcotics? Or even subsidize it? I'm not saying it will happen, but IF sequestox is approved, media will be all over it, and I don't suspect elite will sell above current average opioid prices by that much. Clearly this is my opinion only, but it's not out of the question.
Absolutely it's no joke, with all the political exposure about opioid abuse can you imagine the market for the only ADF labeled immediate release opioid? I can't imagine a physician prescribing anything else to a patient. Think about it, nobody wants the liability, if you had a choice of prescribing 1 of several different options, as a doctor, you go with the safest bet.... IF Elite can surpass the Tmax issue, this drug is literally worth BILLIONS if marketed correctly. It will receive so much media coverage I suspect it will market itself.
If volume is similar tomorrow we might be headed in the right path...
Of course it's my purpose to make money but what does one companies financing issues have to do with another company? EGLT and elite pharmaceuticals are two different entities, what negatively affects the share price of one company has nothing to do with the approval possibility of a drug application for the other
What does that have to do with approval ? EGLTs financing and share price is not the point, The approval is.
I have no idea if it will be approved or not all I can do is speculate, just as others speculate that it will not be approved. That is the purpose of trading. What I do know is my portfolio has gained 15% since I've entered this stock and I expected to run even more. there are several factors that can drive the share price up or down not just FDA approval.
Elite will be the only ADF opioid approved for IMMEDIATE RELEASE.... you know that... EGLT is extended release
It makes a lot of sense, sorry I didn't give you credit it's not like me. I just got overly excited when I read it realizing the implications it has for elite pharmaceuticals and their ADF pipeline...
More like tangerines and mandarins, we'll see soon enough, no matter our opinion the FDA will do what it wants lol
The point isn't just the approval, the point is they voted 18-1 because of the opioid epidemic....take what you want from the article but I see the FDA playing ball here with companies providing abuse deterrent products
EGLT - halted at $9.12 on great news (my remaining shares got auto-sold at 8.81, nice gain from 6.71):
Egalet's long-acting opioid painkiller Arymo wins FDA approval
[Reuters]
January 9, 2017
Jan 9 (Reuters) - The U.S. Food and Drug Administration said on Monday it has approved Egalet Corp's long-acting opioid painkiller, Arymo ER.
An independent panel to the U.S. FDA in August voted 18-1 in favor of approval and recommended the drug be labeled as an abuse-deterrent product by the intravenous, nasal and oral routes of abuse. http://bit.ly/2jv97Ld
The abuse of opioids - a class of drugs that include heroin and prescription painkillers - has long been a concern. An overdose can cause euphoric highs and even disrupt parts of the brain that control breathing.
Lawmakers across the United States are seeking ways to stem the opioid epidemic, which kills 78 Americans every day, according to the U.S. Centers for Disease Control & Prevention.
EGLT just got approved by FDA voted 18-1..... (extended release ADF opioid) ELTP IS NEXT!!!!
No way to know what's in the float?
This is building up stronger support at this level... while the momentum isn't strong the volume at these prices is.... lots of support between .165 and .17...if this continues until PR we might be able to launch from around .20...IMO
Well thanks to FLAFLYERSFAN, we know there are 20bil authorized shares, I don't see this moving anywhere for at least about 100million in volume... maybe some news on the horizon and we're good to go....